Collaboration to advance novel treatment for spasticity
Posted: Mon Mar 05, 2012 11:34 pm
Collaboration to advance novel treatment for spasticity and pain in MS
Concert Pharmaceuticals has joined forces with New York-based Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to fund the pre-clinical advancement of a new drug developed by the company, C-21191, to treat spasticity and pain in people suffering from MS.
“This collaboration with Fast Forward enables us to accelerate development of C-21191 and will provide our team with valuable insight into the management of symptoms associated with multiple sclerosis,” said Roger Tung, president and CEO of Concert Pharmaceuticals. “It further validates our novel deuterated chemical entity platform as a highly efficient approach to creating innovative compounds like C-21191 by leveraging previous industry R&D (research and development) investment.”...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1743
Concert Pharmaceuticals has joined forces with New York-based Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to fund the pre-clinical advancement of a new drug developed by the company, C-21191, to treat spasticity and pain in people suffering from MS.
“This collaboration with Fast Forward enables us to accelerate development of C-21191 and will provide our team with valuable insight into the management of symptoms associated with multiple sclerosis,” said Roger Tung, president and CEO of Concert Pharmaceuticals. “It further validates our novel deuterated chemical entity platform as a highly efficient approach to creating innovative compounds like C-21191 by leveraging previous industry R&D (research and development) investment.”...Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1743